Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 27kWORD 22k
22 August 2019
E-002190/2019(ASW)
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-002190/2019

According to Article 168(7) of the Treaty on the Functioning of the EU(1), the organisation and delivery of health services and medical care is a national competence.

Notwithstanding the above, the EU supports fostering accessible healthcare in Member States. Article 35 of the EU Charter of Fundamental Rights(2) enshrines people’s right of access to treatment and care.

The European Pillar of Social Rights affirms everyone’s right to timely access to affordable, preventive and curative healthcare of good quality(3). The Commission’s contribution to the future of Europe(4), stresses that the EU should support Member States to make their healthcare systems effective, accessible and resilient.

The Commission has supported various relevant initiatives through the EU Health programme(5).

In the Romanian Country Report, published under the most recent European Semester cycle, the Commission has drawn attention to the comparatively low level of spending on healthcare in Romania, notably impacting the coverage of novel medicines(6).

Under the 2019 European Semester, a Country Specific Recommendation was adopted, that underlines the need for Romania to improve access to healthcare(7).

Moreover, the Commission engages through different fora with Member States, including its Pharmaceutical Committee, on issues related to the early availability of centrally authorised medicines, for which the marketing authorisation is granted by the Commission.

(1)https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:12012E/TXT&from=EN
(2)https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:12012P/TXT&from=EN
(3)See Principle 16, https://ec.europa.eu/commission/priorities/deeper-and-fairer-economic-and-monetary-union/european-pillar-social-rights/european-pillar-social-rights-20-principles_en
(4)https://ec.europa.eu/commission/sites/beta-political/files/euco_sibiu_communication_en.pdf
(5)See for instance the development of a Guidance Document on a coordinated approach of national competent authorities regarding the use of ERP to avoid/mitigate negative impact for patient access to medicines, https://webgate.ec.europa.eu/chafea_pdb/health/projects/664317/summary
(6)See in particular page 40, https://ec.europa.eu/info/sites/info/files/file_import/2019-european-semester-country-report-romania_en.pdf
(7)See Country Specific Recommendation 3, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52019DC0523&from=EN

Last updated: 28 August 2019Legal notice